Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service sleep apnea & airway implants cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (12 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 25 | 50% |
| 2020 | 2 | 40 | 51% |
| 2021 | 4 | 16 | 49% |
| 2022 | 6 | 189 | 51% |
| 2023 | 9 | 229 | 53% |
| 2024 | 8 | 239 | 54% |
| 2025 from claims | – | 114 92–134 | 55% |
| 2026 forecast | – | 126 99–158 | 55% |
| 2027 forecast | – | 138 102–183 | 56% |
| 2028 forecast | – | 152 107–209 | 56% |
| 2029 forecast | – | 166 113–238 | 57% |
| 2030 forecast | – | 183 120–271 | 57% |
Hypoglossal nerve stimulation and upper airway procedures. Professional codes (what the surgeon bills): CPT 64582, 64583, 64584, 42145, 41530.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Arizona; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 91% hospital outpatient, 9% surgery center. The share outside the hospital has moved +9 pts since 2022, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 8 | 343+39%/yr | +39%/yr | 0.1 | 11% | 410 in 2030+3.1%/yr |
| Utah | 3 | 142+112%/yr | +112%/yr | 0.6 | 0% | 80 in 2030−8.9%/yr |
| Colorado | 3 | 136+11%/yr | +11%/yr | 0.3 | 0% | 110 in 2030−3.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 46 | 6,368+5.8%/yr | +5.8%/yr | 8.72.1× | 93% | 7,720 in 2030+3.3%/yr |
| Cochlear implants | 8 | 188+10%/yr | +10%/yr | 0.31.6× | 0% | 200 in 2030+1%/yr |
| Ear tubes & middle ear surgery | 1 | 177−6.4%/yr | −6.4%/yr | 0.21.2× | 100% | 150 in 2030−2.6%/yr |
Sleep apnea & airway implants in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Inspire Medical Systems leads with 93% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 8 companies reported engagement with Arizona’s surgeons worth $284K in consulting, speaking, meals and travel tied to these products, about $35K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 18 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.